Showing 2261-2270 of 3039 results for "".
- Orasis Launches Presbyopia Eyedrop Qlosi in the UShttps://modernod.com/news/orasis-launches-presbyopia-eyedrop-qlosi-in-the-us/2482728/Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia in adults is now available to prescribe in the US. Qlosi’s proprietary 'EyeQ Formulation&
- Study: Glaucoma Monitoring Lags in Low-Income and Rural Areashttps://modernod.com/news/study-glaucoma-monitoring-lags-in-low-income-and-rural-areas/2482710/A new Northwestern University study suggests that race, income and where patients live play a major role in the level of care glaucoma patients receive. Researchers found that Black, Hispanic and Asian American patients, as well as those from rural and economically distressed communities, are sig
- Prevent Blindness Announces Matt MacDonald as Chair-Elect of Board of Directorshttps://modernod.com/news/prevent-blindness-announces-matt-macdonald-as-chair-elect-of-board-of-directors/2482708/Prevent Blindness, a nonprofit organization dedicated to eye health and safety awareness, named Matt MacDonald as Chair-elect of its Board of Directors. The vote was held last week during the Spring 2025 Board Meeting. He will succeed current Board of Directors Chair Jim McGrann, CEO of Adva
- Iluvien Earns FDA Approval for Expansion to Treat Chronic Posterior Uveitishttps://modernod.com/news/iluvien-earns-fda-approval-for-expansion-to-treat-chronic-posterior-uveitis/2482704/ANI Pharmaceuticals announced that they the FDA has approved an expanded label for Iluvien to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). “Iluvien's expanded label and the strengthening of our pa
- Bausch + Lomb Launches Arise Orthokeratology Lens System in the UShttps://modernod.com/news/bausch-lomb-announces-arisetm-orthokeratology-lens-system-in-the-united-states/2482702/Bausch + Lomb announced the US launch of Arise, a lens fitting system designed to use intelligent, cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology is a non-surgical method of vision correction that uses rigid, gas-permea
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g
- Mount Sinai Team Identifies Underlying Mechanisms of Age-Related Meibomian Gland Dysfunction, Possible Treatment Options for Dry Eye Diseasehttps://modernod.com/news/mount-sinai-team-identifies-underlying-mechanisms-of-age-related-meibomian-gland-dysfunction-possible-treatment-for-dry-eye-disease/2482679/New research from Mount Sinai identifies an underlying molecular mechanism of age-related degeneration in the meibomian glands essential to normal eye function. Now, this may lead to new therapeutic approaches for common conditions in older adults such as evaporated dry eye disease.
- Alcon Announces US Launch of Systane PRO PF for Dry Eye Reliefhttps://modernod.com/news/alcon-announces-us-launch-of-systane-pro-pf-for-dry-eye-relief/2482678/Alcon has launched Systane PRO Preservative-Free (PF) in the US, the latest addition to its over-the-counter dry eye portfolio. According to Alcon, Systane PRO PF is the longest-lasting eye drop in the Systane lineup, offering a tr
- Glaukos Announces FDA Acceptance of NDA Submission for Epioxahttps://modernod.com/news/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa/2482677/Glaukos announced it has received notification from the FDA acknowledging the previously submitted new drug application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus. The FDA stated that the NDA is sufficien
- New Study Uncovers How Genes Influence Retinal Aging and Brain Healthhttps://modernod.com/news/new-study-uncovers-how-genes-influence-retinal-aging-and-brain-health/2482676/New research from the nonprofit biomedical research institution, The Jackson Laboratory (JAX), reveals that genetics play a key role in how the eye ages, with different genetic backgrounds influencing retinal aging in distinct ways. The study, published in